{"title":"Beneficial Effect of Rebamipide Eye Drops on Blue Light-Induced Oxidative Damage in the Ocular Surface.","authors":"Jingting Liu, Enying Jiang, Hyunjee Kim, Jayoung Moon, Hyeon Jeong Yoon, Kyung Chul Yoon","doi":"10.1089/jop.2024.0208","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> We evaluated the capacity of rebamipide (REB) to alleviate corneal epithelial damage induced via blue light (BL) exposure. <b><i>Methods:</i></b> Eight-week-old C57BL/6 mice were exposed to BL (410 nm, 100 J) twice daily for 10 days. The mice were randomly divided into 5 groups: 1 untreated and 4 groups receiving BL exposure ± different topical treatments: BL exposure alone, carboxymethylcellulose, 5% <i>N</i>-acetylcysteine, and REB. Reactive oxygen species (ROS) levels were assessed, and <i>Bcl-2</i>-associated X protein (<i>BAX) protein</i> was analyzed. Apoptotic cells were detected, inflammatory cytokine levels [tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)] were measured using enzyme-linked immunosorbent assay (ELISA), and histopathological changes in the cornea were evaluated using hematoxylin and eosin (H&E) staining. <b><i>Results:</i></b> The REB group demonstrated significantly lower BL exposure-induced ROS levels (<i>P</i> < 0.01) and <i>BAX</i> expression (<i>P</i> < 0.01) than the BL group. The number of Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive cells were lower in the REB group than in the BL group (<i>P</i> < 0.01). Furthermore, ELISA analysis revealed significantly reduced TNF-α and IL-6 levels in the REB group relative to BL group levels (<i>P</i> < 0.01). Hematoxylin and eosin staining showed preservation of corneal epithelial thickness. <b><i>Conclusions:</i></b> Rebamipide alleviated BL-induced oxidative damage to ocular surfaces by reducing ROS levels, inhibiting apoptosis, and suppressing inflammatory cytokine expression.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2024.0208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We evaluated the capacity of rebamipide (REB) to alleviate corneal epithelial damage induced via blue light (BL) exposure. Methods: Eight-week-old C57BL/6 mice were exposed to BL (410 nm, 100 J) twice daily for 10 days. The mice were randomly divided into 5 groups: 1 untreated and 4 groups receiving BL exposure ± different topical treatments: BL exposure alone, carboxymethylcellulose, 5% N-acetylcysteine, and REB. Reactive oxygen species (ROS) levels were assessed, and Bcl-2-associated X protein (BAX) protein was analyzed. Apoptotic cells were detected, inflammatory cytokine levels [tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)] were measured using enzyme-linked immunosorbent assay (ELISA), and histopathological changes in the cornea were evaluated using hematoxylin and eosin (H&E) staining. Results: The REB group demonstrated significantly lower BL exposure-induced ROS levels (P < 0.01) and BAX expression (P < 0.01) than the BL group. The number of Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive cells were lower in the REB group than in the BL group (P < 0.01). Furthermore, ELISA analysis revealed significantly reduced TNF-α and IL-6 levels in the REB group relative to BL group levels (P < 0.01). Hematoxylin and eosin staining showed preservation of corneal epithelial thickness. Conclusions: Rebamipide alleviated BL-induced oxidative damage to ocular surfaces by reducing ROS levels, inhibiting apoptosis, and suppressing inflammatory cytokine expression.
期刊介绍:
Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders.
Journal of Ocular Pharmacology and Therapeutics coverage includes:
Glaucoma
Cataracts
Retinal degeneration
Ocular infection, trauma, and toxicology
Ocular drug delivery and biotransformation
Ocular pharmacotherapy/clinical trials
Ocular inflammatory and immune disorders
Gene and cell-based therapies
Ocular metabolic disorders
Ocular ischemia and blood flow
Proliferative disorders of the eye
Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.